Investigational Drug Information for AV-101
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug AV-101?
AV-101 is an investigational drug.
There have been 7 clinical trials for AV-101.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 2nd 2022.
The most common disease conditions in clinical trials are Familial Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, and Hypertension. The leading clinical trial sponsors are VistaGen Therapeutics, Inc., Aerovate Therapeutics, and Cato Research.
There are twenty-six US patents protecting this investigational drug and two hundred and eighty-six international patents.
Summary for AV-101
| US Patents | 26 |
| International Patents | 286 |
| US Patent Applications | 102 |
| WIPO Patent Applications | 48 |
| Japanese Patent Applications | 21 |
| Clinical Trial Progress | Phase 2 (2022-11-02) |
| Vendors | 12 |
Recent Clinical Trials for AV-101
| Title | Sponsor | Phase |
|---|---|---|
| Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) | Aerovate Therapeutics | Phase 2/Phase 3 |
| AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia | VistaGen Therapeutics, Inc. | Phase 2 |
| AV-101 Alone and in Combination With Probenecid in Healthy Subjects | Parexel | Phase 1 |
Clinical Trial Summary for AV-101
Top disease conditions for AV-101
Top clinical trial sponsors for AV-101
US Patents for AV-101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AV-101 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| AV-101 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| AV-101 | See Plans and Pricing | Methods for the synthesis of chiral kynurenine compounds | VISTAGEN THERAPEUTICS, INC. (South San Francisco, CA) | See Plans and Pricing |
| AV-101 | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| AV-101 | See Plans and Pricing | Methods and compositions for treating cancer using P2RX2 inhibitors | Flagship Pioneering Innovations V, Inc. (Cambridge, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AV-101
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AV-101 | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| AV-101 | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| AV-101 | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| AV-101 | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| AV-101 | European Patent Office | EP3981392 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
